12/05/2025
💊 GLP-1 Analogues Market Report (2024–2031) 💊
The GLP-1 Analogues Market is forecasted to skyrocket from $14.1B in 2024 to $110B by 2031, growing at a staggering CAGR of 54%. This growth is powered by surging global obesity rates, broader type 2 diabetes treatment adoption, and innovative dual-agonist drug development. Our report decodes pipeline trends, payer dynamics, and market access hurdles.
💡 Key Drivers
📈 Global obesity population >1B ( )
🧬 Expansion into metabolic syndrome & CV risk management
🏥 High patient adherence & positive clinical outcomes
💊 New dual/triple GLP-1/GIP agonists in late-stage trials
🛑 Key Restrainers
💰 Cost burden & access inequalities in LMICs
🧾 Pricing & reimbursement variability across markets
⚠️ Adverse effects: nausea, pancreatitis, adherence drop
📜 Stringent FDA/EMA requirements for obesity indications
Read full report here : https://lnkd.in/ejYsVJ-u
🏆 Top Companies: Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Pfizer, Amgen, Roche, Zealand Pharma, Merck Group, Bayer
🚀 Emerging Companies: Viking Therapeutics, Inc., Altimmune, Inc., Structure Therapeutics, Sciwind Biosciences, Biohaven, Oramed Pharmaceuticals Inc., Chugai Pharmaceutical Co., Ltd., Rhythm Pharmaceuticals Inc., Carmot Therapeutics, Inc.